Conditions: Advanced Renal Cell Carcinoma
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 82
Healthy volunteers: no

Brief summary:
This is a study to evaluate the safety, efficacy and pharmacokinetics of temsirolimus in Asian patients with advanced renal cell carcinoma. The trial is only being conducted in Japan, Korea, and China.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Temsirolimus (CCI-779) intervention 2: Temsirolimus (CCI-779)
Intervention descriptions: intervention 1: 20 mg/m2 IV TEMSR weekly (Japan, n=6) intervention 2: 25 mg IV TEMSR weekly (all other pts)

Protocol document: